ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet
Reimbursing for innovative antibiotics / Encouraging updates from the AMR conference
Plazomicin EU marketing application is withdrawn: Near zero market value of newly approved antibacterials
How hard (and how) to Pull? Net value of Pull via a Transferrable Exclusivity Extension (TEE)
Scary, Scarier, Scariest (Part 2): What can YOU do about it?
What does an antibiotic cost to develop? What is it worth? How to afford it?
FDA workshop: Insights on inhaled antifungals and antibacterials
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
DTR Gram-negative infections: Are new antibiotics making a difference?
COVID-19 and the Long-Term Trajectory of AMR Efforts: Wellcome Trust Deep Dive
New pipeline analysis: Cancer projects were funded 17x more than antibacterials during 2011-2020
New mechanisms for antibiotic reimbursement in the United States: CMS’s IPPS FY2020 Final Rule
Lancet: 10-20-30 targets to address AMR by 2030
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet